Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	478.68B
Revenue (ttm)	8.85B
Net Income (ttm)	-23.12B
Shares Out	37.99M
EPS (ttm)	-677.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,889
Average Volume	125,346
Open	11,750
Previous Close	11,660
Day's Range	10,980 - 12,170
52-Week Range	3,885 - 13,080
Beta	0.63
RSI	67.97
Earnings Date	Aug 13, 2025

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.